Epileptic medications such as Dilantin, Phenytek and Cerebyx have reportedly caused skin blisters and bleeding for some Asian patients. Following such reports, The FDA has begun to keenly monitor these drugs.
Initial investigation suggests that patients with the gene HLA-B1502 carry an enhanced risk of skin reactions upon use of the said drug. Nearly 10% to 15% of patients who have reported such reactions belong to Asia, especially from China, Thailand, and Malaysia.
Victims experienced skin reactions few months after commencing medication.
The agency has directed that the drug carbamazepine, sold under brand names of Tegretol and Carbatrol, be closely monitored for skin reactions.